Pathway-Targeted Therapies in Cancer 2017

The recent successes of targeted therapies highlight both the opportunities and the challenges of personalizing cancer care. The combination of diagnostic tools with targeted agents can provide dramatic patient benefits, but improving the durability of clinical responses requires juxtaposition of clinical and pre-clinical studies to address the underlying disease biology. The opportunity provided by this paradigm is exemplified by our ongoing studies with RG7204, an inhibitor of V600E-BRAF.